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was estimated from €1218 to €1314 per patient/year depending
on different assumptions. These ﬁgures were higher than the
ideal expected average cost derived from guidelines (from €1007
to €1021 per patient/year), so yielding to a potential reduction
of €198 to €293 per patient/year. Monte-Carlo simulation
showed that about 13% of patients in the real word setting pre-
sented higher treatment costs than the maximum expected cost.
This proportion was much higher in moderate/severe patients
compared to mild patients (28.0% and 11.1% respectively).
CONCLUSIONS: An improvement of the adherence to GOLD
guidelines in Spain should have not only clinical implications for
COPD patients, but also an economic beneﬁt for the National
Health System. The potential savings in terms of medications
costs have been estimated around 20% of the observed costs.
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OBJECTIVES: To evaluate the prevalence of pulmonary hyper-
tension (PH) in Germany as epidemiological data for PH are
lacking. METHODS: The study followed a top-down approach,
based on German secondary statistics (based on ICD-10 codes)
and published literature. Several secondary statistics were taken
into account: Ofﬁcial German statistics on nationwide mortality
rates, ADT (“AbrechnungsDatenTransfer”) panel data from
“Zentralinstitut für die kassenärztliche Versorgung”, and diag-
nosis statistics from IMS Health. Data on prevalence of PH
related to connective tissue diseases, HIV infection, chronic
obstructive pulmonary disease (COPD), obstructive sleep apnoea
syndrome (OSAS), left ventricular systolic dysfunction (LVSD)
and pulmonary embolism (PE) were extracted from published lit-
erature 1990 to 2006 (peer-reviewed journals). Numbers of PH
cases were extrapolated for Germany, based on prevalence data
for the underlying diseases. RESULTS: Based on secondary sta-
tistics, number of cases in 2002 with idiopathic pulmonary arte-
rial hypertension (ICD I27.0) ranged from 1400 to almost 2900
cases, and number of cases with unspeciﬁc pulmonary heart
disease (ICD 27.9) ranges from 1700 up to 10,400 cases. Based
on literature data, prevalence of PH in patients with diseases like
connective tissue diseases or HIV infection ranges between 2480
and 11,160 cases. PH caused by LVSD affects about 380,000
patients. Cases of PH associated with COPD, OSAS or PE range
from 191,160 to 496,320. Summing up, between 574,100 and
889,900 patients were estimated to be affected by PH. CON-
CLUSION: The presented analysis is the ﬁrst robust estimation
of the prevalence of PH for Germany. Although the subgroup of
pulmonary arterial hypertension (WHO Group I) is shown to be
rare, secondary forms with estimated 570,000 to 900,000
patients affected by PH should be considered of relevance in
regard to socioeconomic aspects. With respect to these numbers
the medical community should focus on structural aspects of care
for patients with this severe disease.
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OBJECTIVES: To analyse the utilisation of drugs for treatment
of respiratory diseases (ATC group: R) within Slovakia between
1996 and 2004 and to asses the economic consequences of 
the medications. METHODS: For 1996–2004, the data about 
consumption of drugs for treatment of respiratory diseases were
collected, in accordance with classiﬁcation ATC and DDD mea-
surement unit. This analysis focused on the situation in asthma
medication in more detail. Data of wholesalers, who are legally
obliged provide this information to the Slovak Institute for Drug
Control, was used for the analysis. The results were expressed
in the numbers of packages, ﬁnance units (€) and deﬁned daily
doses per 1000 inhabitants per day (DID). RESULTS: A signiﬁ-
cant increase in the medication of respiratory diseases (in 1996
(98.29), in 2000 (92.55) and in 2004 (134.11) in term of DID
can be seen from this analysis. The results show the consump-
tion (in term of DID) of selective beta-2-adrenoreceptor agonists
in 1996 (3.61), in 2000 (3.80) and in 2004 (2.55), adrenergics
in 1996 (1.40), in 2000 (2.04) and in 2004 (5.91), glucocorti-
coids in 1996 (1.43), in 2000 (4.18) and in 2004 (5.26), anti-
cholinergics in 1996 (0.38), in 2000 (1.37) and in 2004 (2.70),
xanthines in 1996 (7.24), in 2000 (8.80) and in 2004 (7.20),
leukotriene receptor antagonists in 1997 (0.03), in 2000 (0.33)
and in 2004 (0.44). In ﬁnancial terms, the consumption of 
selective beta-2-adrenoreceptor agonists (€2,385,000), adrener-
gics (€9,679,000), glucocorticoids (€3,810,000), anticholinergics
(€1,464,000), xanthines (€1,366,000), leukotriene receptor
antagonists (€1,649,000) for the year 2004 can be seen from this
study. CONCLUSIONS: Usage of generic drugs for the treatment
of respiratory diseases brought about a dramatic increase in the
consumption of drugs in this ﬁeld but the ﬁnancial expenditures
for health insurance funds have been remained under control.
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OBJECTIVES: Expected Value of Perfect Information (EVPI)
analysis is a natural extension of probabilistic modelling and
provides information about the value of collecting additional
information to eliminate or reduce uncertainty. A partial EVPI
analysis provides information about the model parameters for
which the collection of additional data is most useful. The objec-
tive of this study is to determine the impact of additional data
collection on the remaining uncertainty in a probabilistic model
for the bronchodilator treatment of patients with chronic
obstructive pulmonary disease (COPD). The value of additional
information is weighted against the costs of collecting the data.
METHODS: We used a probabilistic Markov model with a time-
horizon of 5 years. Primary outcome parameters were the costs
per QALY. Stochastic input parameters of the model included
probabilities to transition between disease states, probabilities to
experience an exacerbation, and utilities and resource use asso-
ciated with disease states and exacerbations. Because utilities
proved to contribute substantially to the overall EVPI, additional
data about utilities associated with COPD severity states were
collected in 1235 patients participating in a randomised clinical
trial. RESULTS: Before collecting additional data the overall
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EVPI was €1368 at a value of the ceiling ratio of €20,000. EVPPI
analysis showed that utilities had the largest contribution to the
overall EVPI. The partial EVPI for this subset of input parame-
ters was €517. Incorporating the newly collected data on utili-
ties into the model reduced the overall EVPI to €563 and the
partial EVPI for the utility input parameter to approximately €0.
CONCLUSIONS: Collecting additional information on utilities
strongly reduced the overall and partial EVPI. At the population
level, the value of collecting additional data on utilities out-
weighed the costs of data collection. Value of information analy-
sis proved to be useful to determine the parameters for which
additional data collection is most beneﬁcial.
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OBJECTIVES: There are currently no well-validated Patient
Reported Outcome (PRO) tools to measure dyspnea in COPD
patients that have been accepted for label claims. Guidelines for
measuring PROs to support label claims encourage patient input
to deﬁne endpoints for clinical trials. This study was designed to
understand COPD patients’ experience of dyspnea, and inform
strategy for measuring PRO endpoints in clinical trials.
METHODS: Seventy-eight individuals (55% male; mean age 58
years) with moderate to severe COPD (MRC grades III-V) across
6 countries participated in interviews/focus groups, describing
their breathing difﬁculties, severity, impacts and ﬂuctuations.
Themes were identiﬁed from a systematic content review of the
transcripts, and further reviewed by an additional 18 patients.
SESULTS: Six distinct sensations of dyspnea were reported, with
patients across multiple cultures demonstrating the ability to dif-
ferentiate between sensations. Patients reported a high level of
diurnal and day-to-day variation in both the nature and severity
of symptoms. A conceptual model was developed based on this
qualitative work and discussion with an expert panel of six clin-
icians and three psychometric experts. Patients conﬁrmed the
multi-sensational nature of dyspnea that is also suggested within
the literature—“a subjective experience of breathing discomfort
that consists of qualitatively distinctive sensations that vary in
intensity”. However, existing measures evaluate dyspnea as a
one-dimensional symptom (a single construct of shortness of
breath) with a broad recall period (one to two weeks). CON-
CLUSIONS: The model showed that a daily diary (with symp-
toms differentiated and assessed by patient-generated descriptive
language) is more relevant for evaluating patients’ experience of
dyspnea in clinical trials. This work demonstrates the value of
extensive, multi-cultural patient input during early stages of PRO
development to ensure that the endpoint strategy for supporting
labelling claims adequately ﬁts the conceptual model for the
patient experience of that condition.
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OBJECTIVES: Tiotropium is a once-daily inhaled anticholiner-
gic maintenance treatment with demonstrated effectiveness in
chronic obstructive pulmonary disease (COPD). We aimed to
compare persistence of tiotropium-use with other respiratory
drugs in COPD in current clinical practice. METHODS: The
PHARMO database includes, among others, drug-dispensing
and hospital discharge records for >2 million subjects in The
Netherlands. All probable COPD-patients were identiﬁed by new
respiratory drug use (age >54 yrs) or COPD-hospitalizations.
New users of tiotropium, ipratropium, long-acting beta-agonists
(LABAs), or ﬁxed combination of inhaled corticosteroids and
LABA (ICS&LABA), in 1998–2003, were included in the study.
Persistence was assessed quarterly during the ﬁrst year of follow-
up. Patients with a proportion of days covered (PDC) ≥80%
were considered persistent. Persistence was analysed using gen-
eralised estimating equations model. RESULTS: About 37% of
new users of tiotropium continued treatment for one year, com-
pared with 14% for ipratropium, 13% for LABA, and 17% for
ICS&LABA. Multivariate analyses showed that tiotropium-users
were 2–3 times more persistent with their therapy than patients
using ipratropium (relative risk [RR]: 2.0; 95% conﬁdence inter-
val [CI]: 1.8–2.3), LABA (RR: 2.9; 95%CI: 2.4–3.6), or
ICS&LABA (RR: 2.4; 95%CI: 2.1–2.8), respectively. Male
gender, age >70 years, pulmonologist as ﬁrst prescriber, prior 
use of other respiratory drugs, and previous hospitalization 
for COPD were all associated with enhanced persistence with 
the initial drug-therapy. CONCLUSIONS: Persistence with
tiotropium was increased compared to other respiratory drugs
in COPD in clinical practice. Additional research is required 
to understand the reasons for these higher persistence levels.
Enhanced treatment persistence may offer beneﬁts to both
patients and society in terms of decreased morbidity and costs.
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OBJECTIVES: Long-term patient adherence to treatment is the
key issue in the efﬁcacy of sublingual immunotherapy (SLIT). To
help clinicians to manage SLIT patients and improve their adher-
ence, a speciﬁc questionnaire: QUARTIS, has been developed
and validated. METHODS: Relevant concepts were identiﬁed
through a combination of literature research and clinician and
patient interviews. After comprehension tests with patients, two
pilot versions, one for patients beginning SLIT (QUARTIS-Start)
and one for patients undergoing SLIT (QUARTIS-Follow-up),
were drawn up and pilot tested in clinical practice. A cross-
sectional observational study including 191 adult patients with
allergic rhinitis beginning SLIT and 381 undergoing SLIT was
conducted to reduce the questionnaires, create their scoring 
and assess their psychometric properties. The ability of the
QUARTIS-Follow-up to predict patients’ intentions to complete
SLIT, motivations to continue the course of SLIT, and adherence
